Literature DB >> 2550643

Lisinopril versus slow-release nifedipine in the treatment of mild to moderate hypertension: a multicentre study. The Cooperative Study Group.

S Witchitz1, A Serradimigni.   

Abstract

The antihypertensive effects of lisinopril 20 mg once daily and slow-release nifedipine 20 mg twice daily were compared in a double-blind, parallel group, 10-week study involving 274 patients with mild to moderate hypertension. During the first 6 weeks of treatment, slow-release nifedipine and lisinopril produced similar reductions in lying and standing blood pressure (BP), except for lying systolic BP (SBP) which was reduced to a greater extent by lisinopril. After 6 weeks of double-blind treatment, hydrochlorothiazide 25 mg once daily was added if BP remained uncontrolled (lying DBP greater than or equal to 95 mmHg); a significantly greater proportion of patients in the nifedipine group than in the lisinopril group required additional diuretic treatment (29% versus 14%, respectively; P = 0.005). Moreover, after a further 4 weeks of treatment BP was adequately controlled (lying DBP less than 95 mmHg) in significantly more lisinopril-treated patients than in the nifedipine group (91.4% versus 78.3%, respectively; P = 0.006). Lisinopril was better tolerated than slow-release nifedipine. The frequency of drug-related events was significantly lower (threefold) for lisinopril than for nifedipine (P = 0.001) and the number of withdrawals from treatment with nifedipine was more than three times that in the lisinopril treatment group (P = 0.009). Lisinopril appears to provide an effective once-daily antihypertensive treatment which is at least as effective as, and better tolerated than, slow-release nifedipine.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2550643

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   3.012


  6 in total

Review 1.  Role of ACE inhibitors in uncomplicated essential hypertension.

Authors:  J I Robertson
Journal:  Br Heart J       Date:  1994-09

Review 2.  Sustained release nifedipine formulations. An appraisal of their current uses and prospective roles in the treatment of hypertension, ischaemic heart disease and peripheral vascular disorders.

Authors:  D Murdoch; R N Brogden
Journal:  Drugs       Date:  1991-05       Impact factor: 9.546

3.  ACE inhibition versus calcium antagonism in the treatment of mild to moderate hypertension: a multicentre study. Ireland-Netherlands Lisinopril-Nifedipine Study Group.

Authors:  W Hart; R J Clarke
Journal:  Postgrad Med J       Date:  1993-06       Impact factor: 2.401

4.  A comparison of lisinopril and nifedipine in the treatment of mild to moderate hypertension. A multicentre study.

Authors:  B Rogstad
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

5.  Hypertension and non-insulin-dependent diabetes. A comparison between an angiotensin-converting enzyme inhibitor and a calcium antagonist.

Authors:  G Crepaldi; A Carraro; E Brocco; L Adezati; D Andreani; G Bompiani; P Brunetti; D Fedele; R Giorgino; G Giustina
Journal:  Acta Diabetol       Date:  1995-10       Impact factor: 4.280

Review 6.  Modified-release nifedipine: a review of the use of modified-release formulations in the treatment of hypertension and angina pectoris.

Authors:  Katherine F Croom; Keri Wellington
Journal:  Drugs       Date:  2006       Impact factor: 11.431

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.